ClinicalTrials.gg
RecruitingNCT04678193COROMECUpdated Mar 20, 2024

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy

An observational study in Covid19, sponsored by Aventyn, Inc.. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by Aventyn, Inc. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Dec 2020; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
27,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Planned enrollment
27th of 521
27,000 · median 300
Started
2020
with 817 others
Observational
521 of 1,860
52 open now
Primary completion
2025-06
later than 36 of 208 live
Registered
791st of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 27th largest by planned enrollment of the 521 observational ones that give a count, is one of 818 that started in 2020, is one of 521 observational ones, reaches primary completion later than 36 of the 208 other live ones, and was the 791st registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact severity of COVID-19 positive and negative subjects and assessment of predictors for post COVID-19 complications. In Phase 2, 2700 subjects with COVID-19 positive test will be studied in the intervention group comparing ECL-19 vs placebo with primary end point of hospital admission assessment. Treatment strategy for PCR positive COVID-19 subjects in the registry who are in Stage I of the disease process with ECL-19 drug compared to placebo in reducing hospital admissions

Read the detailed description

Investigators aim is to create a real time COVID-19 Coromec epidemiology registry to assess the feasibility of monitoring subject infection progress using Vitalbeat digital therapeutics monitoring platform for remote patient monitoring and integrated chronic disease management with mobile app, AI-bot, IoT wearables and cloud computing algorithms developed by health technology company Aventyn, Inc., in collaboration with Intel Corp., clinicians and scientists from Baylor Heart, Abrazo Health, Karolinska Institute, Dignity Health. Coromec registry is a real time epidemiology solution deploying Vitalbeat for pandemic public health stakeholders to enable immediate reporting, assess subject risk prediction for COVID-19 avoiding hospitalization.

The digital health technology aims to assess predictors of risk and predictors of preventing COVID-19, assess what preventive strategies are being used and the efficacy of treatment strategies for avoiding hospitalization. The platform launched globally and is available on the public internet at www.coromec.org

Users can self-report symptoms, mental health assessment, chronic illness status and vital sign measures on a daily basis for risk assessment and preventive treatment with a variety of digital tools by downloading Coromec mobile app, access interactive chatbots and the Coromec real time epidemiology website Researchers aim to study ECL-19 as a drug treatment in stabilizing the endothelium as the first line of approach in COVID 19 positive subjects that may quickly restore their glycocalyx and endothelium thus avoiding hospitalizations and progression of disease with ECL-19

A validated approach would enable vulnerable subjects and communities access to pandemic care. Registry data can assist public health scientists in further studies and enable global registries in future pandemic emergencies to help better understand use of digital tools, intelligent algorithms and predict risk outcomes with targeted novel treatment strategies

03

Conditions studied

  • Covid19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Unselected patient population of COVID 19 positive infection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • COVID-19 PCR positive
  • COVID-19 PCR negative
  • COVID-19 PCR pending
  • COVID-19 high risk score

Exclusion criteria

Exclusion Criteria:

  • Subjects unwilling to participate in the study before, during or after consent
  • Patients considered unreliable by the investigator concerning the requirements for follow-up visits.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
27,000 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • COVID19 PCR positive test and negative or high risk asymptomatic

    Patient population COVID-19 infection risk assessment real time epidemiology with 27000 subjects

  • COVID19 PCR positive test Stage 1 infection

    Patient population of PCR positive COVID-19 Stage 1 infection in registry targeted for ECL-19 treatment for reduced hospitalization with 2700 subjects (10% ECL-19 and 20% Placebo)

    Drug: Coromec Registry with ECL-19

Interventions

  • DrugCoromec Registry with ECL-19

    Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology

    Also known as: Glycocheck

06

What researchers measure

Primary outcomes

  1. Predictors of post COVID-19 complications and predictors of hospitalization

    Measure COVID-19 infection risk score based on PCR Positive Test

    Time frame: 1 Day

  2. Health symptom score

    Measure COVID-19 infection risk score based on health symptoms

    Time frame: 1 Day

  3. Vital signs SpO2 score

    Measure COVID-19 infection high risk score based on vital signs SpO2 \<94%

    Time frame: 1 Day

  4. Vital signs BMI score of 40 kg/m2

    Measure COVID-19 infection high risk score based on Height 0.15 meters and Weight of 122 Kgs

    Time frame: 1 Day

  5. Chronic Illness score

    Measure COVID-19 infection high risk score based on chronic illness response; Yes on uncontrolled Asthma, COPD, Hypertension, T2DM

    Time frame: 1 Day

  6. Mental health assessment high score >11 on PHQ9 Depression score

    Measure COVID-19 infection risk score based on mental health assessment for Depression

    Time frame: 1 Day

  7. Mental health assessment high score >11 on GAD 7 Anxiety score

    Measure COVID-19 infection risk score based on mental health assessment for Anxiety

    Time frame: 1 Day

  8. Evaluate a treatment strategy with ECL-19

    Measure hospital admissions in PCR positive COVID 19 subjects within 48 hours who are in Stage I of the disease process

    Time frame: 1 Day

07

Study locations

3 of 3 sites recruiting
  • Multiple Locations
    Phoenix, Arizona 85016, United States
    Recruiting
    • Puja Chandler · Contact
  • Multiple Locations
    Bangalore, India
    Recruiting
    • Kiran Balakrishna · Contact
  • Multiple Locations
    Stockholm, Sweden
    Recruiting
    • Alexander Eriksson · Contact
08

References and documents

Publications

  • Rovas A, Lukasz AH, Vink H, Urban M, Sackarnd J, Pavenstadt H, Kumpers P. Bedside analysis of the sublingual microvascular glycocalyx in the emergency room and intensive care unit - the GlycoNurse study. Scand J Trauma Resusc Emerg Med. 2018 Feb 14;26(1):16. doi: 10.1186/s13049-018-0483-4. PubMed 29444696 ↗
  • Weissgerber TL, Garcia-Valencia O, Milic NM, Codsi E, Cubro H, Nath MC, White WM, Nath KA, Garovic VD. Early Onset Preeclampsia Is Associated With Glycocalyx Degradation and Reduced Microvascular Perfusion. J Am Heart Assoc. 2019 Feb 19;8(4):e010647. doi: 10.1161/JAHA.118.010647. PubMed 30764695 ↗
  • Rovas A, Seidel LM, Vink H, Pohlkotter T, Pavenstadt H, Ertmer C, Hessler M, Kumpers P. Association of sublingual microcirculation parameters and endothelial glycocalyx dimensions in resuscitated sepsis. Crit Care. 2019 Jul 24;23(1):260. doi: 10.1186/s13054-019-2542-2. PubMed 31340868 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Jun 2025, 54 months after the start.

Of 134 industry-sponsored observational studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 19. This study's planned 54 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Dec 21, 2020
StartActual
Dec 24, 2020
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2026
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04678193
Lead sponsor
Aventyn, Inc.
Collaborators
Intel Corporation, Abrazo Health Network, Karolinska Institutet, ASU College of Health Solutions
Responsible party
Sponsor
First posted
Dec 21, 2020
Start date
Dec 24, 2020
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Mar 20, 2024

Study contacts

Kris Vijay, MD
Contact
coromec@aventyn.com
2317942328
Navin Govind
Contact
coromec@aventyn.com
2317942328
Hans A Vink, PhD
principal investigator · Maastricht University
Michael Castro, MD
principal investigator · Abrazo Health Network
Kris Vijay, MD
study chair · Abrazo Health Network

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion